Cargando…
Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis
BACKGROUND: Extending the original criteria of the Chemoradiotherapy for Oesophageal Cancer followed by Surgery Study (CROSS) in daily practice may increase the treatment outcome of esophageal cancer (EC) patients. This retrospective national cohort study assessed the impact on the pathologic comple...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184698/ https://www.ncbi.nlm.nih.gov/pubmed/33249520 http://dx.doi.org/10.1245/s10434-020-09372-y |
_version_ | 1783704631200710656 |
---|---|
author | Wang, Helena Hong de Heer, Ellen C. Hulshoff, Jan Binne Kats-Ugurlu, Gursah Burgerhof, Johannes G. M. van Etten, Boudewijn Plukker, John Th. M. Hospers, Geke A. P. |
author_facet | Wang, Helena Hong de Heer, Ellen C. Hulshoff, Jan Binne Kats-Ugurlu, Gursah Burgerhof, Johannes G. M. van Etten, Boudewijn Plukker, John Th. M. Hospers, Geke A. P. |
author_sort | Wang, Helena Hong |
collection | PubMed |
description | BACKGROUND: Extending the original criteria of the Chemoradiotherapy for Oesophageal Cancer followed by Surgery Study (CROSS) in daily practice may increase the treatment outcome of esophageal cancer (EC) patients. This retrospective national cohort study assessed the impact on the pathologic complete response (pCR) rate and surgical outcome. PATIENTS AND METHODS: Data from EC patients treated between 2009 and 2017 were collected from the national Dutch Upper Gastrointestinal Cancer Audit database. Patients had locally advanced EC (cT1/N+ or cT2-4a/N0-3/M0) and were treated according to the CROSS regimen. CROSS (n = 1942) and the extended CROSS (e-CROSS; n = 1359) represent patients fulfilling the original or extended CROSS criteria, respectively. The primary outcome was total pCR (ypT0N0), while secondary outcomes were local esophageal pCR (ypT0), surgical radicality, and postoperative morbidity and mortality. RESULTS: Overall, CROSS and e-CROSS did not differ in total or local pCR rate, although a trend was observed (23.2% vs. 20.4%, p = 0.052; and 26.7% vs. 23.8%, p = 0.061). When stratifying by histology, the pCR rate was higher in the CROSS group compared with e-CROSS in squamous cell carcinomas (48.2% vs. 33.3%, p = 0.000) but not in adenocarcinomas (16.8% vs. 16.9%, p = 0.908). Surgical radicality did not differ between groups. Postoperative mortality (3.2% vs. 4.6%, p = 0.037) and morbidity (58.3% vs. 61.8%, p = 0.048) were higher in e-CROSS. CONCLUSION: Extending the CROSS inclusion criteria for neoadjuvant chemoradiotherapy in routine clinical practice of EC patients had no impact on the pCR rate and on radicality, but was associated with increased postoperative mortality and morbidity. Importantly, effects differed between histological subtypes. Hence, in future studies, we should carefully reconsider who will benefit most in the real-world setting. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1245/s10434-020-09372-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-8184698 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-81846982021-06-25 Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis Wang, Helena Hong de Heer, Ellen C. Hulshoff, Jan Binne Kats-Ugurlu, Gursah Burgerhof, Johannes G. M. van Etten, Boudewijn Plukker, John Th. M. Hospers, Geke A. P. Ann Surg Oncol Thoracic Oncology BACKGROUND: Extending the original criteria of the Chemoradiotherapy for Oesophageal Cancer followed by Surgery Study (CROSS) in daily practice may increase the treatment outcome of esophageal cancer (EC) patients. This retrospective national cohort study assessed the impact on the pathologic complete response (pCR) rate and surgical outcome. PATIENTS AND METHODS: Data from EC patients treated between 2009 and 2017 were collected from the national Dutch Upper Gastrointestinal Cancer Audit database. Patients had locally advanced EC (cT1/N+ or cT2-4a/N0-3/M0) and were treated according to the CROSS regimen. CROSS (n = 1942) and the extended CROSS (e-CROSS; n = 1359) represent patients fulfilling the original or extended CROSS criteria, respectively. The primary outcome was total pCR (ypT0N0), while secondary outcomes were local esophageal pCR (ypT0), surgical radicality, and postoperative morbidity and mortality. RESULTS: Overall, CROSS and e-CROSS did not differ in total or local pCR rate, although a trend was observed (23.2% vs. 20.4%, p = 0.052; and 26.7% vs. 23.8%, p = 0.061). When stratifying by histology, the pCR rate was higher in the CROSS group compared with e-CROSS in squamous cell carcinomas (48.2% vs. 33.3%, p = 0.000) but not in adenocarcinomas (16.8% vs. 16.9%, p = 0.908). Surgical radicality did not differ between groups. Postoperative mortality (3.2% vs. 4.6%, p = 0.037) and morbidity (58.3% vs. 61.8%, p = 0.048) were higher in e-CROSS. CONCLUSION: Extending the CROSS inclusion criteria for neoadjuvant chemoradiotherapy in routine clinical practice of EC patients had no impact on the pCR rate and on radicality, but was associated with increased postoperative mortality and morbidity. Importantly, effects differed between histological subtypes. Hence, in future studies, we should carefully reconsider who will benefit most in the real-world setting. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1245/s10434-020-09372-y) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-11-28 2021 /pmc/articles/PMC8184698/ /pubmed/33249520 http://dx.doi.org/10.1245/s10434-020-09372-y Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Thoracic Oncology Wang, Helena Hong de Heer, Ellen C. Hulshoff, Jan Binne Kats-Ugurlu, Gursah Burgerhof, Johannes G. M. van Etten, Boudewijn Plukker, John Th. M. Hospers, Geke A. P. Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis |
title | Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis |
title_full | Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis |
title_fullStr | Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis |
title_full_unstemmed | Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis |
title_short | Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis |
title_sort | effect of extending the original cross criteria on tumor response to neoadjuvant chemoradiotherapy in esophageal cancer patients: a national multicenter cohort analysis |
topic | Thoracic Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184698/ https://www.ncbi.nlm.nih.gov/pubmed/33249520 http://dx.doi.org/10.1245/s10434-020-09372-y |
work_keys_str_mv | AT wanghelenahong effectofextendingtheoriginalcrosscriteriaontumorresponsetoneoadjuvantchemoradiotherapyinesophagealcancerpatientsanationalmulticentercohortanalysis AT deheerellenc effectofextendingtheoriginalcrosscriteriaontumorresponsetoneoadjuvantchemoradiotherapyinesophagealcancerpatientsanationalmulticentercohortanalysis AT hulshoffjanbinne effectofextendingtheoriginalcrosscriteriaontumorresponsetoneoadjuvantchemoradiotherapyinesophagealcancerpatientsanationalmulticentercohortanalysis AT katsugurlugursah effectofextendingtheoriginalcrosscriteriaontumorresponsetoneoadjuvantchemoradiotherapyinesophagealcancerpatientsanationalmulticentercohortanalysis AT burgerhofjohannesgm effectofextendingtheoriginalcrosscriteriaontumorresponsetoneoadjuvantchemoradiotherapyinesophagealcancerpatientsanationalmulticentercohortanalysis AT vanettenboudewijn effectofextendingtheoriginalcrosscriteriaontumorresponsetoneoadjuvantchemoradiotherapyinesophagealcancerpatientsanationalmulticentercohortanalysis AT plukkerjohnthm effectofextendingtheoriginalcrosscriteriaontumorresponsetoneoadjuvantchemoradiotherapyinesophagealcancerpatientsanationalmulticentercohortanalysis AT hospersgekeap effectofextendingtheoriginalcrosscriteriaontumorresponsetoneoadjuvantchemoradiotherapyinesophagealcancerpatientsanationalmulticentercohortanalysis AT effectofextendingtheoriginalcrosscriteriaontumorresponsetoneoadjuvantchemoradiotherapyinesophagealcancerpatientsanationalmulticentercohortanalysis |